Tags: Life Sciences
WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team will discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
Are parallel importers necessarily allowed to rebox medicines in case of visible traces from ATDs? The CJEU says NO
Pharmaceutical companies are obliged to affix an anti-tampering device (‘ATD’) on prescription-only medicines to enable verification of whether a medicine’s packaging has been tampered with. Parallel importers argue that this results in an overarching objective necessity to ‘rebox’ such medicines.
WEBINAR VIDEO | Life Sciences Session #9: Hot topics in healthcare tendering
Please join us on 28 November 2022 from 13:30 to 14:30 for our ninth online Life Sciences Session, where Caroline De Mulder and Kirian Claeyé will discuss the latest evolutions in the field of healthcare public procurement and will answer questions such as:
Can parallel importers (re)brand generic medicines? The CJEU limits the ‘room for manoeuvre’
If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine? After the Brussels Court of Appeal had referred questions on this issue for a preliminary ruling two years ago, the CJEU has now clarified the limits.
New rules on medical force majeure and the medical certificate
A new Act, which includes various provisions on incapacity for work, was published in the Belgian State Gazette on 18 November 2022.
Invisible life to the rescue: European Commission facilitates approval of micro-organisms in plant protection products from 21 November 2022
Micro-organisms or microbes (e.g. bacteria, fungi or protozoa) are invisible to us but play a significant ecological role as they help to break down organic matter and produce oxygen. Some of them protect crops from pests and diseases, making them a suitable alternative to chemical-based plant protection. Given its ambition […]
Life Sciences Session #9: Hot topics in healthcare tendering
Our Life Sciences team is taking the initiative to offer you short, digestible and regular online Life Sciences Sessions.
European Commission Unveils Measures to Unleash the Potential of Health Data
The European Commission has presented its Proposal for a Regulation on the European Health Data Space (the “Proposal”). While it aims to strengthen the rights of individuals and unlock data’s potential for research purposes, it also adds complexity to an already extensive legal framework.
Brussels and Brussels South Charleroi Airports fined for use of thermal cameras
The Belgian Data Protection Authority has fined Brussels Airport and Brussels South Charleroi Airport 200,000 and 100,000 EUR respectively for their use of thermal cameras during the Covid-19 pandemic.
Webinar video | Life Sciences Session #8: Global MAs and regulatory data protection a substantive and procedural challenge
Our speakers Philippe de Jong and Kirian Claeyé discuss the interesting judgment of the General Court in Polpharma v. EMA.
Belgian competition authority hits pharmaceutical wholesalers with cartel fine
Belgian companies active in the pharmaceutical sector at different levels should beware of competition law.